Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Individualized Surgical Management for Thyroglossal Duct Cyst‐Papillary Thyroid Carcinoma: A Case Series
Dahiya, Rockey , Weiss, Natalie , May, Ryan, Chindris, Ana‐Maria , Janus, Jeffrey R. , Pirgousis, Phillip , May, Ryan, Chindris, Ana-Maria , Reynolds, Jordan

The Laryngoscope | July 12, 2025 | Volume: 135 | Issue: 10 | Pages: 3951-3956

10.1002/lary.32403 | PMID 40650637 Get It

ABSTRACTObjectivesThyroglossal duct cyst (TGDC) associated carcinoma is rare, accounting for less than 2% of TGDC cases. The majority of cases are classified as papillary thyroid carcinoma (PTC). Standard treatment for TGDC‐PTC involves a Sistrunk procedure and prophylactic total thyroidectomy (TT). However, the necessity of these extensive surgical interventions remains debated. This report aims to explore whether individualized surgical approaches may reduce morbidity while maintaining favorable oncological outcomes.MethodsRetrospective case series of three patients with TGDC‐PTC.ResultsThe age range at presentation for our patients with TGDC‐PTC was 26 to 50. Case 1 involved a 38‐year‐old patient with a cystic mass near the hyoid bone and submental lymphadenopathy who underwent cyst excision with level Ia lymph node clearance. Case 2 is of a 50‐year‐old patient with a history of TGDC‐PTC who presented with a recurrent neck mass 9 years after the initial surgery and underwent a revision Sistrunk procedure. Case 3 presents a 26‐year‐old patient with a large TGDC and a benign thyroid nodule who underwent a Sistrunk procedure. All three patients had PTC confirmed by final pathology. All had no evidence of recurrent disease at follow‐up evaluations ranging from 1 to 12 years.ConclusionThis case series demonstrates the feasibility and safety of individualized surgical management for TGDC‐PTC. Risk stratification allowed for tailored interventions and avoided overly aggressive approaches. Further studies are needed to establish definitive guidelines for managing TGDC‐PTC, particularly in low‐risk patients.Level of Evidence4.
The Geriatric Emergency Care Applied Research Standardization Study ( GEARSS ): An Observational Study of Older Emergency Department Patients
Hwang, Ula , Sifnugel, Natalia, Cohen, Inessa , Han, Ling, Araujo, Katy, Bianco, Luann, Capelli, Sandra, Cruz, Daniel S. , Fishman, Ivy L., Gipson, Katrina, Hung, William W. , Kang, Raymond , Lockhart, Mechelle, Ohuabunwa, Ugochi , Ottilie‐Kovelman, Sierra, Partridge, Caitlin, Platts‐Mills, Timothy F. , Sandoval, Jacqueline , Taylor, Zachary , Tomasino, Debra F. , Vaughan, Camille P. , Tomasino, Debra F , Vaughan, Camille P , Hwang, Ula , Brandt, Cynthia , Carpenter, Christopher R. , Dresden, Scott M. , Hastings, Susan N. , Meeker, Daniella , Taylor, Zachary

Academic Emergency Medicine | July 12, 2025 | Volume: 33 | Issue: 1 | Pages: No page available

10.1111/acem.70101 | PMID 40650481 Get It

ABSTRACT Objectives Multicenter research of geriatric emergency department (GED) care remains limited. Our objectives were to: 1. Prospectively collect data prioritized by the Geriatric Emergency care Applied Research (GEAR) network, a transdisciplinary taskforce for GED care, and create a multicenter GED research repository of prospective and electronic health record (EHR) data, 2. Assess concordance between prospective and EHR data. Methods The GEAR Standardization Study (GEARSS) is a multicenter, prospective study of older emergency department (ED) patients (65+) focusing on the 4Ms of age‐friendly care (mobility, medication safety, mentation, what matters) and elder mistreatment. Demographic and clinical data were collected via interviews by trained research assistants (RA) on Days 0, 4, 30, and 90 and linked to EHR. Prevalence of chronic comorbidities and incident delirium were measured and reported using descriptive statistics. Prospective and EHR data concordance was assessed with Cohen's Kappa. Results 999 participants were recruited from 5 EDs (3/25/2021–6/30/2022) across 3 institutions: Grady Health System, Northwestern Memorial Hospital, and Yale New Haven Health. The cohort was 57.0% female, 55.2% White, 39.1% Black, and 3.4% Hispanic, and the mean age was 75.1 years. For rheumatologic disease, peptic ulcer disease, diabetes, renal disease, and cancer, prevalence differed between prospective and EHR data by > 10%. About two‐thirds of participants were at risk for falls. Concordance between prospective and EHR data was good for ethnicity ( K = 0.73); excellent for sex ( K = 1.00), age ( K = 1.00), and race ( K = 0.98); fair for disposition ( K = 0.53); slight for ED observation status ( K = 0.33) and dementia diagnosis ( K = 0.24); poor for delirium presence ( K = 0.07). Conclusion In GEARSS, demographic variables aligned strongly between prospective and EHR data, while diagnosis, disposition, and mentation factors did not. This multicenter data source provides preliminary findings for common geriatric syndromes and conditions. Choice of measures using these data should be driven by GED research questions.
Telling Women to “Lean in” Isn't Going to Cut It
Walker, Laura , Lee, Moon O. , Fang, Andrea , Elia, Tala , Schoenfeld, Elizabeth , Walker, Laura E , Schoenfeld, Elizabeth M

Academic Emergency Medicine | July 12, 2025 | Volume: 32 | Issue: 11 | Pages: 1259-1261

10.1111/acem.70105 | PMID 40650479 Get It

Composition-on-composition regression analysis for multi-omics integration of metagenomic data
Rios, Nicholas , Shi, Yuke, Chen, Jun , Zhan, Xiang , Li, Qizhai , Chen, Jun , Xue, Lingzhou

Bioinformatics | July 12, 2025 | Volume: 41 | Issue: 7 | Pages: No page available

10.1093/bioinformatics/btaf387 | PMID 40650352 Get It

Abstract Motivation Compositional data are frequently encountered in many disciplines, such as in next-generation sequencing experiments widely used in biomedical studies. Regression analysis with compositional data as either responses or predictors has been well studied. However, when both responses and predictors are compositional, the inventory of analysis tools is surprisingly limited, especially in the high-dimensional setting. Among the few existing methods, most of them rely on a log-ratio transformation to move compositional data from the simplex to real numbers. Yet, a serious weakness of these methods is their failure to handle the substantial fraction of zeroes observed in data collected from next-generation sequencing experiments. Results To investigate associations between two high-dimensional multi-omics compositions, we propose a composition-on-composition (COC) regression analysis method which does not require log-ratio transformations and hence can handle zeroes in the data. To account for high dimensionality, we estimate regression coefficients using a penalized estimation equation approach. Finally, inference procedures for COC regression are also proposed. Superior performance of COC is demonstrated through both comprehensive numerical simulations and case studies. Availability and implementation Source R codes to implement COC method is available at https://github.com/nrios4/COC.
Anaplastic large cell lymphoma: unusual clinical and pathologic findings: A report of the 2023 SH-EA4HP Lymphoma Workshop
Marques‐Piubelli, Mario L. , Feldman, Andrew L. , Feldman, Andrew L , Xu, Jie , Hsi, Eric D. , Miranda, Roberto N. , Medeiros, L. Jeffrey

American Journal of Clinical Pathology | July 12, 2025 | Volume: 164 | Issue: 1 | Pages: 110-125

10.1093/ajcp/aqaf029 | PMID 40646678 Get It

Abstract Anaplastic large cell lymphoma (ALCL) cases were discussed at the 2023 Society of Hematopathology/European Association for Haematopathology workshop held on November 9-11, 2023, in Houston, Texas. This session focused on the clinical and pathologic spectrum of 3 types of ALCL: anaplastic lymphoma kinase (ALK)-positive, ALK-negative, and breast implant associated (BIA). Cases of primary cutaneous ALCL were excluded because they were included in another session. Although the diagnosis of ALCL is often straightforward, the 42 submitted cases encompassed unusual clinical presentations, morphologic variants, and atypical immunophenotypes, exemplifying potential difficulties and challenges in establishing the diagnosis of ALCL. Distinguishing ALCL from CD30-positive peripheral T-cell lymphoma, not otherwise specified, or classic Hodgkin lymphoma was discussed. In patients with a previous history of mycosis fungoides and other T-cell lymphoma/leukemia, the differential diagnosis of a CD30-positive T-cell lymphoma mimicking ALCL (mycosis fungoides transformation vs de novo ALCL) was also discussed. In patients with suspected BIA-ALCL, it is critical to properly handle the periprosthetic fluid when the disease first presents and the capsule at the time of initial capsulectomy to make a correct diagnosis and pathologic staging because a missed diagnosis may lead to disease progression. Comprehensive immunohistochemical analysis; fluorescence in situ hybridization for DUSP22, TP63, or JAK2 rearrangement; assessment of clonality of the T-cell receptor and immunoglobulin genes; and sequencing for mutations were performed as part of the workup of the submitted cases, particularly on ALK-negative ALCL cases, emphasizing the importance of ancillary testing in establishing the diagnosis.
MAYOCTransformer: Masked-Attention for Yielding Comprehensive Semantic Segmentation of Retinal Optical Coherence Tomography Images using Transformer-based Neural Networks
Krivit, Jenna, Reiter, Gregor S. , Iezzi, Raymond , Ye, Run Zhou

No container title available | July 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.07.08.663601 Get It

ABSTRACT Purpose Optical coherence tomography (OCT) is a widely used imaging modality in ophthalmology. Accurate semantic segmentation of these images is critical for both clinical and research applications, yet existing convolutional neural network (CNN)-based methods face challenges in generalizability and robustness. This study introduces MAYOCTransformer, the first transformer-based deep learning model for comprehensive semantic segmentation of OCT images, and evaluates its performance against CNN-based models. Methods A large dataset of 3,500 OCT images was manually segmented using an iterative deep learning-assisted workflow. The MAYOCTransformer model, based on the Mask2Former architecture, was trained and compared against CNN-based segmentation models, including U-Net, U-Net++, FPN, and DeepLabV3+. Comprehensive segmentation tasks included 10 retinal layer segmentation, choroid stroma and vessel segmentation, and the identification of 9 types of discrete pathological findings including intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), subretinal hyper-reflective material (SHRM), intraretinal hyper-reflective foci, and reticular pseudodrusen. Model performance was evaluated using the Dice similarity coefficient (DSC) on a hold-out test set with five-fold cross-validation. Additional validation was performed using external datasets, open-source segmentation models, and a randomized blinded expert evaluation. Results MAYOCTransformer outperformed CNN-based models in most segmentation tasks. Choroid segmentation performance was comparable between MAYOCTransformer and CNN models. External validation demonstrated the model’s generalizability, achieving higher DSC scores than publicly available segmentation models. A blinded expert evaluation showed that MAYOCTransformer’s segmentation was non-inferior to manual annotations. Conclusion MAYOCTransformer provides improved segmentation performance over CNN-based models. Its ability to generalize to external datasets suggests potential applicability in clinical and research settings.
Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial
Aizer, Ayal A. , Tanguturi, Shyam , Catalano, Paul J. , Shin, Kee‐Young , Ricca, Ivy, Johnson, Marciana, Benham, Grant, Kozono, David , Mak, Raymond H. , Hertan, Lauren , Chipidza, Fallon , Krishnan, Monica, Pashtan, Itai , Peng, Luke , Shiloh, R., Cagney, Daniel , Brown, Paul D. , Wen, Patrick Y. , Haas‐Kogan, Daphne A. , Rahman, Rifaquat , Tanguturi, Shyam K , Shi, Diana , Catalano, Paul J , Shin, Kee-Young , Ricca, Ivy , Kozono, David E , Mak, Raymond H , Chipidza, Fallon , Qian, Jack M , Sands, Jacob M , Brown, Paul D , Wen, Patrick Yung , Haas-Kogan, Daphne , Rahman, Rifaquat , Shi, Diana D. , Sands, Jacob

Journal of Clinical Oncology | July 11, 2025 | Volume: 43 | Issue: 27 | Pages: 2986-2997

10.1200/jco-25-00056 | PMID 40644657 Get It

PURPOSE Stereotactic radiation (SRS/SRT) as opposed to whole-brain radiation (WBRT) represents the standard of care for patients with a limited number of brain metastases given the relatively favorable toxicity profile associated with stereotactic treatment. However, in patients with small cell lung cancer (SCLC), WBRT remains standard because of a lack of prospective data supporting SRS/SRT and concerns related to intracranial progression and neurologic death when WBRT is omitted. We conducted a single-arm, multicenter, phase II trial of SRS/SRT in patients with SCLC and 1-10 brain metastases to assess neurologic death rates relative to historical controls managed with WBRT (ClinicalTrials.gov identifier: NCT03391362 ). METHODS Patients were eligible if they had SCLC or an extrathoracic small cell primary and 1-10 brain metastases. Previous brain-directed radiation including prophylactic cranial irradiation was not permitted. Neurologic death was defined as marked, progressive, radiographic brain progression accompanied by corresponding neurologic symptomatology without systemic disease progression or systemic symptoms of a life-threatening nature. Close imaging-based surveillance of the brain post-SRS/SRT was used. RESULTS Between February 2018 and April 2023, 100 patients were enrolled. The median number of brain metastases was 2 (IQR, 1-4; range, 1-10). The median overall survival was 10.2 months; only 22% of patients required salvage WBRT. In total, 20 neurologic deaths were observed, relative to 64 non-neurologic deaths. The neurologic death rate at 1 year was 11.0% (95% CI, 5.8 to 18.1); the historical rate in patients managed with WBRT was 17.5%. CONCLUSION Our prospective, multi-institutional study demonstrated low rates of neurologic death when SRS/SRT as opposed to WBRT is used in patients with SCLC and 1-10 brain metastases who are surveilled closely post-treatment, supporting the utility of stereotactic approaches in this population.
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
Montalban‐Bravo, Guillermo , Loghavi, Sanam , Li, Ziyi , Chien, Kelly S. , Kanagal‐Shamanna, Rashmi , Natu, Anuya , Gurney, Mark E. , Bazinet, Alexandre , Sasaki, Koji , Kadia, Tapan M. , Ravandi, Farhad, Pemmaraju, Naveen , Finke, Christy M. , Al‐Kali, Aref , Gangat, Naseema , Mangaonkar, Abhishek A. , Bueso‐Ramos, Carlos E. , Tefferi, Ayalew, Kantarjian, H., Garcia‐Manero, Guillermo , Patnaik, Mrinal M. , Kantarjian, Hagop M. , Chien, Kelly , Gurney, Mark , Sasaki, Koji , DiNardo, Courtney , Daver, Naval , Short, Nicholas , Pemmaraju, Naveen , Issa, Ghayas , Al-Kali, Aref , Csizmar, Clifford , Gangat, Naseema , Patnaik, Mrinal , Loghavi, Sanam , Kanagal-Shamanna, Rashmi , Kantarjian, Hagop , Bataller, Alex , Hammond, Danielle , Borthakur, Gautam , Swaminathan, Mahesh , DiNardo, Courtney D. , Ravandi, Farhad , Daver, Naval , Short, Nicholas J. , Lasho, Terra L. , Csizmar, Clifford M. , Alkhateeb, Hassan B. , Tefferi, Ayalew

Blood Advances | July 11, 2025 | Volume: 9 | Issue: 19 | Pages: 5105-5117

10.1182/bloodadvances.2025016529 | PMID 40644618 Get It

Abstract RAS pathway (RASp) mutations induce proliferative features, and promote transformation in chronic myelomonocytic leukemia (CMML). However, the unique clonal landscape and hierarchy of distinct RASp mutations remain unexplored. To characterize the landscape, architecture, and implications of unique RASp mutations in CMML, we evaluated a cohort of 814 patients with CMML. We identified 461 RASp mutations among 342 patients (42%). N/KRAS and CBL mutations were the most common, frequently involved the P-loop or RING domains, respectively, and frequently appeared as dominant events (63% and 65%, respectively). BRAF, NF1, and PTPN11 mutations spanned throughout the gene structure, and frequently appeared as subclonal events (75%, 64%, and 59%, respectively). CBL mutations frequently occurred in codominance with SRSF2 and multihit TET2, and were enriched for KIT mutations. PTPN11 mutations more frequently co-occurred with SETBP1 and DNMT3A mutations, and were infrequently codominant with TET2 or ASXL1. RASp mutations predicted for shorter overall survival (hazard ratio [HR], 1.55; 95% confidence interval [CI], 1.15-2.07; P = .0075) and leukemia-free survival (LFS; HR, 1.67; 95% CI, 1.26-2.20; P = .0011), influenced outcomes of myelodysplastic and TET2 mutant CMML, and cooperated with IDH2 and RUNX1 mutations to induce shorter LFS. These data set the bases for refined genomic classifications of CMML, and underscore the need to develop RAS-directed therapies for patients with CMML.
Thalamocortical network neuromodulation for epilepsy
Osman, Gamaleldin , Starnes, Keith , Sheffield, W. D., Leyde, Kent, Stead, Matt, Brinkmann, Benjamin H. , Miller, Kai J. , Gregg, Nicholas M. , Alcalá-Zermeño, Juan Luis , Osman, Gamaleldin M, Brinkmann, Benjamin H , Lundstrom, Brian Nils , Gregg, Nicholas M , Starnes, Donnie Keith , Agashe, Shruti , Sheffield, W Douglas, Stead, Matt, Gompel, Jamie J. Van , Worrell, Gregory A. , Lundstrom, Brian N.

Brain Communications | July 11, 2025 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/braincomms/fcaf270 | PMID 40980408 Get It

Abstract Despite the growing interest in network-guided neuromodulation for epilepsy, uncertainty about the safety and long-term efficacy of thalamocortical stimulation persists. Our evaluation focused on the use of a four-lead open-loop implantable pulse generator for thalamocortical network neuromodulation. We retrospectively reviewed seven patients with diverse seizure networks—poorly localized, regional, or multifocal—undergoing thalamocortical neuromodulation. Employing a four-lead system, electrodes targeted both thalamic and cortical seizure network nodes. We assessed seizure severity, life satisfaction and sleep quality on a 10-point scale, and seizure frequency was assessed via telephone interviews and chart review. Outcomes were assessed by the Wilcoxon sign-rank test at the 0.05 significance level. Seven patients with a median age at implant of 22 years (range 14–42 years) had a median disabling seizure reduction of 93% (range 50–100%, P = 0.0156), with 100% responder rate (≥50% reduction in seizure frequency) after a median of 17 months post-implantation (range 13–60). The median improvement in seizure severity was 3.5 out of 10 points (P = 0.0312), life satisfaction 4.5 points (P = 0.0312) and quality of sleep 3 points (P = 0.062). No perioperative complications occurred. Transient seizure exacerbations (n = 2) and stimulation-related sensory/motor side-effects (n = 2) quickly resolved with parameter adjustments. One patient required surgical revision due to delayed infection. Six patients had permanent electrode placement refined by intracranial EEG trial stimulation; five patients had >90% reduction in seizure frequency during trial stimulation. Thalamocortical network neuromodulation using a four-lead open-loop system is safe and associated with significant improvements in seizure control and patient quality of life. Trial stimulation during intracranial EEG shows promise for enhancing seizure network engagement and parameter optimization but requires further study. Prospective controlled trials are needed to further characterize and validate the efficacy and side-effect profile of thalamocortical network neuromodulation for epilepsy.
AMCP Market Insights: Payer best practices in food allergy management
Richardson, Terry , Wescott, Susan, Gupta, Ruchi , Haumschild, Ryan, Kobernick, Michael, Albright, Joseph, Abdo, Mike, Bioc, Justin, Richardson, Terry, Gupta, Ruchi, Albright, Joseph

Journal of Managed Care & Specialty Pharmacy | July 11, 2025 | Volume: 31 | Issue: 8-b Suppl | Pages: S1-S12

10.18553/jmcp.2025.31.8-b.s1 | PMID 40644324 Get It